Обертамиг

Rec. INN (наименование, зарегистрированное ВОЗ)

2750126-32-8

immunoglobulin half IG G1-lambda2/scFv-h-CH2-CH3, anti-[Homo sapiens CD3E (CD3 epsilon)] and anti-[Homo sapiens HLA-G (class I major histocompatibility (MH1) antigen G, human leucocyte antigen G) C-like domain], Homo sapiens monoclonal antibody, bispecific, bivalent; gamma1 heavy chain anti-CD3E Homo sapiens (1-450) [VH (Homo sapiens IGHV6-1*01 (88.1%) -(IGHD) - IGHJ4*01 (100%), CDR-IMGT [10.9.10] (26-35.53-61.100-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, G1v14-67 CH2 A1.3, A1.2, S27, G1v69 V6, Y7, A85.1, V86 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 L1.3>A (237) , L1.2>A (238), D27>S (268) (234-343), CH3 E12 (359), M14 (361), T6>V (353), L7>Y (354), F85.1>A (408), Y86>V (410) (344-448), CHS (449-450)) (121-450)], (223-216')-disulfide with lambda light chain anti-CD3E Homo sapiens (1'-216') [V-LAMBDA (Homo sapiens IGLV2-23*02 (84.4%) -IGKJ2*01 (90.9%), CDR-IMGT [9.3.10] (26-34.52-54.91-100)) (1'-110') -Homo sapiens IGLC2*01 (100%) (111'-216')]; IG scFv-h-CH2-CH3 chain single chain, anti-HLA-G Homo sapiens (1''-452'') [scFv V-kappa-VH anti-HLA-G (1''-258'') [V-KAPPA (Homo sapiens IGKV4-1*01 (96.0%) -IGKJ1*01 (100%), CDR-IMGT [12.3.9] (27-38.56-58.95-103)) (1''-113'') -20-mer linker (114''-133'') -VH (Homo sapiens IGHV6-1*01 (99.0%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [10.9.15] (159-168.186-194.233-247)) (134''-258'')] -Homo sapiens IGHG1*03 h-CH2-CH3, nG1m1 CH3 E12, M14, G1v37 h S5, G1v14-67 CH2 A1.3, A1.2, S27, G1v68 CH3 V6, L22, L79; W81 (259''-490'') [hinge 1-15 C5>S (263) (259''-273''), CH2 L1.3>A (277), L1.2>A (278), D27>S (308) (274''-383''), CH3 T6>V (393), E12 (399), M14 (401), T22>L (409), K79>L (435), T81>W (437) (384''-488''), CHS (489''-490'')]]; dimer (229-269'':232- 272'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

Поделиться этой страницей